A participant in the company’s late-stage coronavirus vaccine trial reportedly developed severe neurological symptoms. Now experts must assess whether the vaccine was responsible.
Source: New York Times
Safety Review Begins Into AstraZeneca's Coronavirus Vaccine Trial
More from AstraZeneca PLCMore posts in AstraZeneca PLC »
- J.&J. Vaccine May Be Less Effective Against Delta, Study Suggests
- Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine
- Three Studies, One Result: Vaccines Point the Way Out of the Pandemic
- Vaccines Are Effective Against the New York Variant, Studies Find
- The Pfizer-BioNTech Vaccine Is Said to Be Powerfully Protective in Adolescents
More from Clinical TrialsMore posts in Clinical Trials »
- Why a Century-Old Vaccine Offers New Hope Against Pathogens
- Why Monkeypox Vaccine Shortage May Threaten the Immunocompromised
- Vaccines for Young Children Are Coming, but Many Parents Have Tough Questions
- A Better Way to Measure Immunity in Children
- New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claims
More from Coronavirus (2019-nCoV)More posts in Coronavirus (2019-nCoV) »
More from Great BritainMore posts in Great Britain »
- In the Lives of the Tudors, Hints of the Present-Day Monarchy
- Prince Andrew Settles Sexual Abuse Lawsuit With Virginia Giuffre
- Woman Suing Prince Andrew for Abuse Settled With Epstein for $500,000
- Woman Suing Prince Andrew for Abuse Settled With Jeffrey Epstein for $500,000
- 17 New York Arts Organizations Are Among Those Receiving $30 Million
More from Vaccination and ImmunizationMore posts in Vaccination and Immunization »
- New Covid Booster Shots Cut Risk of Hospitalization by Half, CDC Reports
- Will Covid Boosters Prevent Another Wave? Scientists Aren’t So Sure.
- Why It Was Easier to Curb Monkeypox Than Covid
- NYC Ends Monkeypox Emergency and Mobile Vaccine Vans
- Scientists Are Gaining On RSV, a Persistent Threat to Children
More from your-feed-healthcareMore posts in your-feed-healthcare »
Be First to Comment